Randomized Phase II Study of Everolimus (E) Versus Everolimus plus Bevacizumab (E plus B) in Patients (Pts) With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET), CALGB 80701 (Alliance)
Publication
, Journal Article
Kulke, MH; Niedzwiecki, D; Foster, NR; Fruth, B; Kunz, PL; Kennecke, H; Wolin, EM; Venook, AP
Published in: PANCREAS
March 1, 2016
Duke Scholars
Published In
PANCREAS
EISSN
1536-4828
ISSN
0885-3177
Publication Date
March 1, 2016
Volume
45
Issue
3
Start / End Page
477 / 477
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Gastroenterology & Hepatology
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Kulke, M. H., Niedzwiecki, D., Foster, N. R., Fruth, B., Kunz, P. L., Kennecke, H., … Venook, A. P. (2016). Randomized Phase II Study of Everolimus (E) Versus Everolimus plus Bevacizumab (E plus B) in Patients (Pts) With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET), CALGB 80701 (Alliance). PANCREAS, 45(3), 477–477.
Kulke, Matthew H., Donna Niedzwiecki, Nathan R. Foster, Briant Fruth, Pamela L. Kunz, Hagen Kennecke, Edward M. Wolin, and Alan P. Venook. “Randomized Phase II Study of Everolimus (E) Versus Everolimus plus Bevacizumab (E plus B) in Patients (Pts) With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET), CALGB 80701 (Alliance).” PANCREAS 45, no. 3 (March 1, 2016): 477–477.
Kulke MH, Niedzwiecki D, Foster NR, Fruth B, Kunz PL, Kennecke H, et al. Randomized Phase II Study of Everolimus (E) Versus Everolimus plus Bevacizumab (E plus B) in Patients (Pts) With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET), CALGB 80701 (Alliance). PANCREAS. 2016 Mar 1;45(3):477–477.
Kulke, Matthew H., et al. “Randomized Phase II Study of Everolimus (E) Versus Everolimus plus Bevacizumab (E plus B) in Patients (Pts) With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET), CALGB 80701 (Alliance).” PANCREAS, vol. 45, no. 3, LIPPINCOTT WILLIAMS & WILKINS, Mar. 2016, pp. 477–477.
Kulke MH, Niedzwiecki D, Foster NR, Fruth B, Kunz PL, Kennecke H, Wolin EM, Venook AP. Randomized Phase II Study of Everolimus (E) Versus Everolimus plus Bevacizumab (E plus B) in Patients (Pts) With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET), CALGB 80701 (Alliance). PANCREAS. LIPPINCOTT WILLIAMS & WILKINS; 2016 Mar 1;45(3):477–477.
Published In
PANCREAS
EISSN
1536-4828
ISSN
0885-3177
Publication Date
March 1, 2016
Volume
45
Issue
3
Start / End Page
477 / 477
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Gastroenterology & Hepatology
- 3202 Clinical sciences
- 1103 Clinical Sciences